Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cases of delayed presentation. Current agents that can be used in cases of delayed presentation of nerve damage by thrombus. Current systemic thrombolytic therapy is associated with adverse effects such as fibrinogenolysis and bleeding. In an attempt to increase the efficacy, safety, and specificity of thrombolytic therapy, a number of targeted thrombolytic agents have been studied in recent years. This review focuses on the concepts underlying targeted thrombolytic therapy and describes recent drug developments in this field.
Keywords: NSFC grant; cerebral hemorrhage; cerebrovascular disease; fibrin targeting; fibrinolytic mechanism; fibrinolytic system; nerve regeneration; neural regeneration; neuroprotective drug; platelet targeting; red blood cell targeting; review; stroke; thrombolytic agent.